A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Part of paid clinical trials in Arcadia, California.
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT06491914
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Diabetic Macular Edema
- Neovascular Age-Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept 8 mg — DRUGAdministered by intravitreal (IVT) injection
Study Details
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications. The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.
Key Dates
- Start date
- Jul 24, 2024
- Status verified
- Oct 2025
- Primary completion
- Aug 26, 2025
- Completion
- Jan 7, 2027
Study Design
- Enrollment
- 1,118 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Aflibercept 8 mgParticipants previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications
Primary Outcome Measure
Occurrence of treatment-emergent adverse events (TEAEs) [ Time Frame: Through week 24 ]
Locations (53)
Find similar trials in Arcadia, CA
By condition
By specialty
By research site
Win Retina - Arcadia· Arcadia, CACalifornia Retina Consultants· Bakersfield, CARetina Specialists of Beverly Hills· Beverly Hills, CASalehi Retina Institute dba Retina Associates of Southern California· Huntington Beach, CASouth Coast Retina Center· Long Beach, CACalifornia Eye Specialists Medical Group, Inc.· Pasadena, CA
Related Studies
- Extension Study for the Port Delivery System With Ranibizumab (Portal)PHASE3 · Recruiting · Hoffmann-La Roche · Phoenix, Arizona
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)PHASE4 · Recruiting · Genentech, Inc. · Mesa, Arizona
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)PHASE1 · Recruiting · Ocugen · Deerfield Beach, Florida